Prostate cancer is the second leading cause of death from cancer in men in the U.S. and mortality from prostate cancer is invariably due to tumor metastasis. Our overall goals for this second competitive renewal application therefore continue to be to understand prostate cancer invasion and metastasis with a focus, in this application, on lymphatic metastasis and malignant ascites. During the previous funding period we have obtained novel insights into metastasis-permissive environments and the role of hypoxia in this process. Based on these insights, and as a logical progression of understanding the metastatic phenotype in prostate cancer, in Aims 1 and 2 we have focused on understanding the role of hypoxia in allowing lymphatic and ascites metastatic dissemination from metastasis-permissive environments, and on characterizing the role of extracellular matrix in this process, using noninvasive optical and MR imaging.
In Aim 3 we intend to investigate the role of cancer cell- lymphatic endothelial cell interactions in cancer cell invasion under hypoxic conditions, using our MR compatible cell perfusion system. The studies proposed here will characterize extracellular matrix integrity and structure and the role of lymphatic endothelial cells in microenvironments that permit metastasis, and the role of hypoxia in facilitating metastasis from these environments. These studies will also provide insight into the dynamics governing interstitial transport and the mechanisms of clearance of macromolecular fluid in tumors in hypoxic and normoxic tumor regions. The proposed studies will continue to identify vascular, physiological and metabolic characteristics which promote invasion and metastasis. This information is critical for developing strategies to prevent metastasis from prostate cancer.
Lymphatic metastasis and malignant ascites are major causes of poor prognosis and quality of life in prostate cancer patients. Hypoxic environments frequently exist in solid tumors and result resistance to therapy. Here we intend to use noninvasive MRI methods as well as optical microscopy and immunohistochemistry to understand the role of metastasis-permissive environments and hypoxia in altering interstitial fluid transport and the extracellular matrix, and in lymphatic metastasis and malignant ascites in preclinical studies of prostate cancer.
|Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339|
|Chen, Zhihang; Krishnamachary, Balaji; Penet, Marie-France et al. (2018) Acid-degradable Dextran as an Image Guided siRNA Carrier for COX-2 Downregulation. Theranostics 8:1-12|
|Penet, Marie-France; Kakkad, Samata; Pathak, Arvind P et al. (2017) Structure and Function of a Prostate Cancer Dissemination-Permissive Extracellular Matrix. Clin Cancer Res 23:2245-2254|
|Krishnamachary, Balaji; Stasinopoulos, Ioannis; Kakkad, Samata et al. (2017) Breast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts. Oncotarget 8:17981-17994|
|Shah, Tariq; Wildes, Flonne; Kakkad, Samata et al. (2016) Lymphatic endothelial cells actively regulate prostate cancer cell invasion. NMR Biomed 29:904-11|
|Jin, Jiefu; Krishnamachary, Balaji; Mironchik, Yelena et al. (2016) Phototheranostics of CD44-positive cell populations in triple negative breast cancer. Sci Rep 6:27871|
|Penet, Marie-France; Jin, Jiefu; Chen, Zhihang et al. (2016) Magnetic Resonance Imaging and Spectroscopy in Cancer Theranostic Imaging. Top Magn Reson Imaging 25:215-221|
|Winnard Jr, Paul T; Bharti, Santosh K; Penet, Marie-France et al. (2016) Detection of Pancreatic Cancer-Induced Cachexia Using a Fluorescent Myoblast Reporter System and Analysis of Metabolite Abundance. Cancer Res 76:1441-50|
|Penet, Marie-France; Chen, Zhihang; Mori, Noriko et al. (2016) Magnetic Resonance Spectroscopy of siRNA-Based Cancer Therapy. Methods Mol Biol 1372:37-47|
|Chen, Zhihang; Penet, Marie-France; Krishnamachary, Balaji et al. (2016) PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer. Biomaterials 80:57-67|
Showing the most recent 10 out of 63 publications